uniQure N.V. (0EE0.L)
USD 16.7
(1.06%)
USD 16.7
(1.06%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 138.4 Million USD | -3.14% |
| 2022 | 142.89 Million USD | 5.28% |
| 2021 | 135.72 Million USD | 89.71% |
| 2020 | 71.54 Million USD | -2.08% |
| 2019 | 73.06 Million USD | 105.97% |
| 2018 | 35.47 Million USD | 75.82% |
| 2017 | 20.17 Million USD | -0.3% |
| 2016 | 20.23 Million USD | -4.47% |
| 2015 | 21.18 Million USD | 1.08% |
| 2014 | 20.95 Million USD | 87.6% |
| 2013 | 11.17 Million USD | 1777.12% |
| 2012 | 595.12 Thousand USD | 155.1% |
| 2011 | 233.29 Thousand USD | -20.63% |
| 2010 | 293.92 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 67.59 Million USD | -87.35% |
| 2024 Q2 | 534.44 Million USD | -1.49% |
| 2024 Q1 | 542.49 Million USD | 291.95% |
| 2023 Q2 | 139.08 Million USD | -2.05% |
| 2023 FY | 138.4 Million USD | -3.14% |
| 2023 Q1 | 141.99 Million USD | -0.63% |
| 2023 Q4 | 138.4 Million USD | 0.08% |
| 2023 Q3 | 138.29 Million USD | -0.57% |
| 2022 Q1 | 135.4 Million USD | -0.23% |
| 2022 FY | 142.89 Million USD | 5.28% |
| 2022 Q4 | 142.89 Million USD | 3.01% |
| 2022 Q3 | 138.72 Million USD | -0.28% |
| 2022 Q2 | 139.11 Million USD | 2.74% |
| 2021 Q1 | 105.41 Million USD | 47.34% |
| 2021 Q3 | 107.02 Million USD | -0.04% |
| 2021 Q4 | 135.72 Million USD | 26.82% |
| 2021 FY | 135.72 Million USD | 89.71% |
| 2021 Q2 | 107.06 Million USD | 1.57% |
| 2020 Q2 | 71.14 Million USD | -2.04% |
| 2020 FY | 71.54 Million USD | -2.08% |
| 2020 Q1 | 72.62 Million USD | -0.59% |
| 2020 Q4 | 71.54 Million USD | 0.23% |
| 2020 Q3 | 71.37 Million USD | 0.33% |
| 2019 Q4 | 73.06 Million USD | 2.03% |
| 2019 Q3 | 71.6 Million USD | -0.42% |
| 2019 FY | 73.06 Million USD | 105.97% |
| 2019 Q1 | 62.78 Million USD | 77.0% |
| 2019 Q2 | 71.91 Million USD | 14.54% |
| 2018 Q4 | 35.47 Million USD | 71.29% |
| 2018 Q3 | 20.7 Million USD | -0.77% |
| 2018 Q2 | 20.86 Million USD | 0.26% |
| 2018 Q1 | 20.81 Million USD | 0.11% |
| 2018 FY | 35.47 Million USD | 75.82% |
| 2017 FY | 20.17 Million USD | -0.3% |
| 2017 Q3 | 20.58 Million USD | 0.55% |
| 2017 Q1 | 20.36 Million USD | 0.63% |
| 2017 Q4 | 20.79 Million USD | 1.0% |
| 2017 Q2 | 20.47 Million USD | 0.54% |
| 2016 Q3 | 21.18 Million USD | 0.25% |
| 2016 FY | 20.23 Million USD | -4.47% |
| 2016 Q2 | 21.13 Million USD | 0.55% |
| 2016 Q1 | 21.01 Million USD | -0.78% |
| 2016 Q4 | 20.23 Million USD | -4.48% |
| 2015 Q2 | 21.56 Million USD | 1.73% |
| 2015 FY | 21.18 Million USD | 1.08% |
| 2015 Q4 | 21.18 Million USD | -0.16% |
| 2015 Q3 | 21.21 Million USD | -1.62% |
| 2015 Q1 | 21.19 Million USD | 1.16% |
| 2014 Q4 | 20.95 Million USD | 0.67% |
| 2014 Q2 | 20.31 Million USD | 98.4% |
| 2014 Q3 | 20.81 Million USD | 2.47% |
| 2014 Q1 | 10.23 Million USD | -0.39% |
| 2014 FY | 20.95 Million USD | 87.6% |
| 2013 Q1 | - USD | -100.0% |
| 2013 Q2 | 31.56 Million USD | 0.0% |
| 2013 Q4 | 10.27 Million USD | -3.65% |
| 2013 Q3 | 10.66 Million USD | -66.2% |
| 2013 FY | 11.17 Million USD | 1777.12% |
| 2012 Q4 | 595.12 Thousand USD | 0.0% |
| 2012 FY | 595.12 Thousand USD | 155.1% |
| 2011 FY | 233.29 Thousand USD | -20.63% |
| 2010 FY | 293.92 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | -278.829% |
| Dynavax Technologies Corporation | 256.91 Million USD | 46.126% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -233.299% |
| Perrigo Company plc | 4.07 Billion USD | 96.602% |
| Illumina, Inc. | 2.26 Billion USD | 93.881% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 99.604% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -13740.9% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 98.551% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 99.027% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 20.342% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 94.879% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -412.816% |
| Waters Corporation | 2.35 Billion USD | 94.124% |
| Biogen Inc. | 7.33 Billion USD | 98.114% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -263.24% |
| Evolus, Inc. | 126.54 Million USD | -9.374% |
| Adicet Bio, Inc. | 17.7 Million USD | -681.839% |
| Cara Therapeutics, Inc. | 43.16 Million USD | -220.636% |
| bluebird bio, Inc. | 330.32 Million USD | 58.099% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 74.414% |
| FibroGen, Inc. | 170.45 Million USD | 18.8% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 94.939% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -562.744% |
| Homology Medicines, Inc. | 44.05 Million USD | -214.18% |
| Geron Corporation | 85.89 Million USD | -61.13% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 94.228% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 68.901% |
| Myriad Genetics, Inc. | 145 Million USD | 4.546% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -10884.841% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | -19.995% |
| Zoetis Inc. | 6.8 Billion USD | 97.965% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -3044.23% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 93.615% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 87.793% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 82.879% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -281.051% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 90.478% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | -139.164% |
| Verastem, Inc. | 41.55 Million USD | -233.058% |
| Nektar Therapeutics | 230.4 Million USD | 39.927% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | 25.735% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -4402.57% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 90.091% |
| OPKO Health, Inc. | 326.56 Million USD | 57.617% |
| Exelixis, Inc. | 189.94 Million USD | 27.132% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 67.692% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -91561.589% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Imunon, Inc. | 1.13 Million USD | -12048.675% |
| Blueprint Medicines Corporation | 774.12 Million USD | 82.121% |
| Insmed Incorporated | 1.2 Billion USD | 88.504% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 90.768% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -142.874% |
| TG Therapeutics, Inc. | 110.79 Million USD | -24.924% |
| Incyte Corporation | 38.28 Million USD | -261.504% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 84.227% |